Systemic and Mucosal Immunizations with Fibronectin-binding Protein FBP54 Induce Protective Immune Responses Against Streptococcus Pyogenes Challenge in Mice

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2001 Feb 13

PMID 11159987

Citations 34

Authors

S Kawabata

E Kunitomo

Y Terao

I Nakagawa

K Kikuchi

K Totsuka

S Hamada

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to examine the suitability of fibronectin-binding protein FBP54 as a putative vaccine for Streptococcus pyogenes infections. When the distribution of the fbp54 gene among the clinical isolates representing various M serotypes was tested by PCR and Southern blot assays, it was found that all of the strains possess this gene. Furthermore, a significant increase in immunoglobulin G (IgG) antibody titers against FBP54 was observed in sera from patients with S. pyogenes infections compared with those from healthy volunteers (P < 0.005). Mice were immunized with FBP54 subcutaneously, orally, or nasally. An enzyme-linked immunosorbent assay revealed that antigen-specific IgG antibodies were induced in the sera of immunized mice, while high salivary levels of IgA antibodies were detected after oral and nasal immunizations. Mice subcutaneously or orally immunized with FBP54 survived significantly longer following the challenge with S. pyogenes than did nonimmunized mice (P < 0.001). These results indicate that FBP54 is a promising vaccine for the prevention of S. pyogenes infections.

Citing Articles

Invasion of pancreatic ductal epithelial cells by Enterococcus faecalis is mediated by fibronectin and enterococcal fibronectin-binding protein A.

Shimosaka M, Kondo J, Sonoda M, Kawaguchi R, Noda E, Nishikori K Sci Rep. 2025; 15(1):2585.

PMID: 39833342 PMC: 11747100. DOI: 10.1038/s41598-025-86531-9.

Sulfated motifs in heparan sulfate inhibit adhesion onto fibronectin and attenuate corneal infection.

Hayashida A, Saeed H, Zhang F, Song Y, Liu J, Parks W Proteoglycan Res. 2024; 1(3).

PMID: 38957622 PMC: 11218895. DOI: 10.1002/pgr2.9.

Interplay between group A and host innate immune responses.

Su M, Cheng Y, Lin Y, Wu J Microbiol Mol Biol Rev. 2024; 88(1):e0005222.

PMID: 38451081 PMC: 10966951. DOI: 10.1128/mmbr.00052-22.

Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.

Iyer V, Sagar V, Toor D, Lyngdoh V, Nongrum G, Kapoor M Cureus. 2023; 14(12):e33146.

PMID: 36721580 PMC: 9884514. DOI: 10.7759/cureus.33146.

Pangenome analysis and virulence profiling of Streptococcus intermedius.

Sinha D, Sun X, Khare M, Drancourt M, Raoult D, Fournier P BMC Genomics. 2021; 22(1):522.

PMID: 34238216 PMC: 8266483. DOI: 10.1186/s12864-021-07829-2.

References

Kawabata S, Terao Y, Fujiwara T, Nakagawa I, Hamada S . Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice. Infect Immun. 1999; 67(11):5863-8. PMC: 96967. DOI: 10.1128/IAI.67.11.5863-5868.1999. View

Lancefield R . Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962; 89:307-13. View

Dale J, Beachey E . Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein. J Exp Med. 1986; 163(5):1191-202. PMC: 2188111. DOI: 10.1084/jem.163.5.1191. View

Gaworzewska E, Colman G . Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol Infect. 1988; 100(2):257-69. PMC: 2249231. DOI: 10.1017/s095026880006739x. View

Bronze M, Beachey E, Dale J . Protective and heart-crossreactive epitopes located within the NH2 terminus of type 19 streptococcal M protein. J Exp Med. 1988; 167(6):1849-59. PMC: 2189697. DOI: 10.1084/jem.167.6.1849. View

Fenderson P, Fischetti V, Cunningham M . Tropomyosin shares immunologic epitopes with group A streptococcal M proteins. J Immunol. 1989; 142(7):2475-81. View

Fischetti V . Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev. 1989; 2(3):285-314. PMC: 358122. DOI: 10.1128/CMR.2.3.285. View

Martin P, Hoiby E . Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis. 1990; 22(4):421-9. DOI: 10.3109/00365549009027073. View

Musser J, Hauser A, Kim M, Schlievert P, Nelson K, Selander R . Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A. 1991; 88(7):2668-72. PMC: 51299. DOI: 10.1073/pnas.88.7.2668. View

10.

Hasty D, Ofek I, Courtney H, Doyle R . Multiple adhesins of streptococci. Infect Immun. 1992; 60(6):2147-52. PMC: 257136. DOI: 10.1128/iai.60.6.2147-2152.1992. View

11.

Hanski E, Caparon M . Protein F, a fibronectin-binding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes. Proc Natl Acad Sci U S A. 1992; 89(13):6172-6. PMC: 402144. DOI: 10.1073/pnas.89.13.6172. View

12.

Johnson D, Stevens D, Kaplan E . Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis. 1992; 166(2):374-82. DOI: 10.1093/infdis/166.2.374. View

13.

Relf W, Martin D, Sriprakash K . Identification of sequence types among the M-nontypeable group A streptococci. J Clin Microbiol. 1992; 30(12):3190-4. PMC: 270620. DOI: 10.1128/jcm.30.12.3190-3194.1992. View

14.

Robinson J, Kehoe M . Group A streptococcal M proteins: virulence factors and protective antigens. Immunol Today. 1992; 13(9):362-7. DOI: 10.1016/0167-5699(92)90173-5. View

15.

Hoge C, Schwartz B, Talkington D, Breiman R, MacNeill E, Englender S . The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA. 1993; 269(3):384-9. View

16.

Demers B, Simor A, Vellend H, Schlievert P, Byrne S, Jamieson F . Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis. 1993; 16(6):792-800; discussion 801-2. DOI: 10.1093/clind/16.6.792. View

17.

Dale J, Chiang E, Lederer J . Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol. 1993; 151(4):2188-94. View

18.

Wessels M, Goldberg J, Moses A, DiCesare T . Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A streptococci. Infect Immun. 1994; 62(2):433-41. PMC: 186126. DOI: 10.1128/iai.62.2.433-441.1994. View

19.

Courtney H, Li Y, Dale J, Hasty D . Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. Infect Immun. 1994; 62(9):3937-46. PMC: 303051. DOI: 10.1128/iai.62.9.3937-3946.1994. View

20.

Rakonjac J, Robbins J, Fischetti V . DNA sequence of the serum opacity factor of group A streptococci: identification of a fibronectin-binding repeat domain. Infect Immun. 1995; 63(2):622-31. PMC: 173041. DOI: 10.1128/iai.63.2.622-631.1995. View